Another year of innovative research and development (R&D) to help patients around the world live longer, healthier lives has flown by. Beginning April 9, leaders from the biopharmaceutical industry, patient advocates, regulators, academics and others will gather in Washington, D.C. for this year’s PhRMA Annual Meeting.
This month, a New York Times editorial discussed the cost of a new drug to treat hepatitis C. The opinion piece took a short-term view of treating the disease, noting that a panel of experts concluded that the drug offered “low value” for treating most patients, in large part due to its cost.
Helen Keller once said, “Alone we can do so little; together we can do so much.”While all members of the biopharmaceutical industry are working toward the common goal of improving patient health, it is through collaboration that we have seen diseases eradicated and innovative treatments emerge from the pipeline. This week, we highlight some of the collaborative efforts currently underway to help patients across the world.
This week’s Medicines in Development report for Parkinson’s disease examines the work currently underway to help the 1.5 million Americans who are affected by the progressive neurological condition. While high-profile Parkinson’s patients like Michael J.
The magnificent architecture of the South Carolina State House served as the backdrop for Diabetes under the Dome – an event obviously focusing on one of the state’s worst health nightmares: diabetes.
In January, the Centers for Medicaid and Medicare Services (CMS) issued a proposed rule that would have adversely altered Medicare Part D’s six protected classes for prescription medication, restricting Medicare beneficiary access to antidepressants and immunosuppressants beginning in 2015.
The development of new medical breakthroughs depends on the patients who volunteer to participate in clinical trials, but according to the Center for Information and Study on Clinical Research Participation, only 6 percent of clinical trials are completed on time and half of clinical research sites enroll one or no patients in their study.
This week we focused on the role of patients within the R&D process, from discovery to market access.
You could have heard a pin drop as onetime clinical trial participant Laura Hull spoke at yesterday's "Research in Your Backyard" event in Winston-Salem, N.C. More than a few eyes had tears in them.
The recent spotlight on prescription drug abuse has overshadowed an important patient population that must deal with chronic pain everyday. Addicts, overdoses and mentions of the “opioid epidemic” in the media has made is increasingly difficult for the people who depend on these medicines to be able to get them.
Each patient is unique, which means that medicines and therapies often need to be tailored to fit individual needs to ensure the best possible care. While the research and development (R&D) pipeline holds the promise of new, innovative treatments for those suffering from a variety of diseases, it is important to explore all options to improve patient health.
A patient should never have to worry about the safety of their medicines. Unfortunately, patient’s lives are put at risk across the country due to counterfeit, substandard, or otherwise unsafe medicines.
Since taking effect in 2006, Medicare Part D has provided seniors with critical access to the prescription medications they need. As part of the program, patients have broader access to medicines that fall into one of six “protected classes” that include anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals and immunosuppressants.
This post originally appeared on the Age of Personalized Medicine.
Since the Accelerating Medicines Partnership (AMP) was announced last month, there’s been robust discussion throughout the scientific community and the general public about the goals of this unique partnership between the National Institutes of Health (NIH), several non-profit disease foundations, 10 biopharmaceutical compani
Patients, physicians, biopharmaceutical companies, and the federal government all want the same thing: New treatment options to save lives from diseases that claim far too many.
The Sunshine Act encourages transparency around the interactions between physicians and biopharmaceutical professionals. These conversations are vital to improving patient care.